VTRS · available-data snapshot
Viatris Inc. (VTRS): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Viatris Inc. (VTRS); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 20, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 20, 2026 · How these pages are made
Why is there no fair value for VTRS?
We do not publish a fair value for Viatris Inc.. What we can say from its filings and market data is below.
What is VTRS's TickerWorth Score?
Cheap against our estimate — but a weaker business
Compared with Healthcare companies in US
Its strongest point: looks cheap on the numbers. Its weakest: balance sheet looks stretched.
our cash-flow model doesn't fit this business, so we won't award our top grade off the remaining lenses
- Value · 90 of 100
Cheaper than 90% of Healthcare companies in US
- Price vs worth · 100 of 100
- Quality · 36 of 100
More profitable than 36% of Healthcare companies in US
- Financial health · 25 of 100
Financially stronger than 25% of Healthcare companies in US
- Growth · 30 of 100
Growing faster than 30% of Healthcare companies in US
- Momentum · 94 of 100
Outperformed 94% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $18.26
- Market cap
- $20,
973, 268, 992 - 52-week high
- $18.75
- 52-week low
- $9.92
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 20, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Viatris Inc. (VTRS) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, VTRS trades at a recent price of $18.26, a market capitalisation of about $20,973,268,992, sitting 94% of the way up its 52-week range ($9.92–$18.75), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing VTRS's trading multiples against a sector benchmark. Here that gives Fwd P/E of 6.8× (cheaper than the peer median of 17.4×); P/B of 1.5× (cheaper than the peer median of 7.8×); P/S of 1.4× (cheaper than the peer median of 6.2×); EV/EBITDA of 7.7× (cheaper than the peer median of 18.3×); Dividend yield of 2.6% (cheaper than the peer median of 2.4%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. VTRS shows a price-to-book (P/B) of 1.48 and book value of $12.34 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. VTRS is in an up-trend (price above both its 50- and 200-day averages), trading -2.6% from its 52-week high. Over the past year the stock is +79.6%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
VTRS vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | VTRS | Peer median | Read |
|---|---|---|---|
| Fwd P/E | 6.8× | 17.4× | cheaper than |
| P/B | 1.5× | 7.8× | cheaper than |
| P/S | 1.4× | 6.2× | cheaper than |
| EV/EBITDA | 7.7× | 18.3× | cheaper than |
| Dividend yield | 2.6% | 2.4% | cheaper than |
What does Viatris Inc. do?
What does it do?
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector), headquartered in United States. The company employs roughly 30,000 people.
How does it make money?
The business turns $14.3B in annual revenue into profit. Out of every $100 of sales, about $13 is left as operating profit (operating margin of 12.6%), after a 40% gross margin on the products/services it sells. After all costs, taxes and interest, -2.8% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (1.0× equity), comfortably covers its short-term bills (1.6× current ratio), and is currently lossmaking.
Who at VTRS filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Enrietti Andrew | See Remarks | Option exercise | — | Form 4 for Enrietti Andrew (opens sec.gov in a new tab) | |
| Enrietti Andrew | See Remarks | Shares withheld (tax) | $177,410.13 | Form 4 for Enrietti Andrew (opens sec.gov in a new tab) | |
| Enrietti Andrew | See Remarks | Option exercise | — | Form 4 for Enrietti Andrew (opens sec.gov in a new tab) | |
| Enrietti Andrew | See Remarks | Shares withheld (tax) | $7,060.05 | Form 4 for Enrietti Andrew (opens sec.gov in a new tab) | |
| Campbell Paul | See Remarks | Open-market sale | $809,784.00 | Form 4 for Campbell Paul (opens sec.gov in a new tab) | |
| Le Goff Corinne | Chief Commercial Officer | Option exercise | — | Form 4 for Le Goff Corinne (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.